RLS Global AB (publ) Year-end Report, 2019

Report this content

October 1st - December 31st
• Net sales amounted to kSEK 54 (1,131)
• The operating loss for the period was MSEK -8.9 (-5.9)
• Earnings per share after dilution at SEK -0.15 (-0.10)
• Cash flow from operating activities amounted to MSEK -5.7 (-5.0)
• Cash and cash equivalents amounted to MSEK 41.8 (22.6)

January 1st - December 31st
• Net sales amounted to kSEK 1,023 (2,621)
• Earnings before interest and taxes (EBIT) amounted to MSEK -26.7 (-21.9)
• Earnings per share after dilution SEK -0.44 (-0.37)
• Cash flow from operating activities amounted to MSEK -24.9 (-21.7)
• Liquid assets at the end of the period at MSEK 41.8 (22.6)
• Equity ratio was 90 percent (84)


Notable events during fourth quarter
• Our first order for ChloraSolv received and delivered
• A pre-RFD application to FDA has been submitted
• New pre-clinical evaluations has been performed through the collaboration with RISE
• An evaluation of the current Business strategy for the Dental portfolio has been initiated
• RLS has finalized all the preparation work to secure MDR compliance in May 2020
• OneMed has signed agreement for ChloraSolv with five municipalities
• RLS has prepared documentation for submission of a public tender in one of the largest regions in Sweden


Important events after the period
• Our clinical study ChloraSolv01 successfully included all patients
• Audits by Lloyd’s, regarding our Quality Management System and Eurofins, our new notified body, of the Medical Device Directive with good results and new certificates were issued
• RLS has initiated market access activities for Norway and Denmark
• The Board has decided to discontinue the Dental business. Different opportunities are under evaluation

Notable events during the year
During the first quarter
• January 1st - CariSolv and Perisolv are leading products for efficient and substance-preserving treatment of caries and periodic deseases and will be distributed exclusively by Unident with operations in Sweden, Norway, Denmark and Finland (except PeriSolv in Norway)
• March 13th - 15th – RLS Global is attending IDS Conference together with Straumann and participate during the launch of “Next Generation Dentistry”


During the second quarter
• ChloraSolv was CE approved and cleared for commercial launch in EU
• The Company was granted a bank loan to secure the financing an additional year
• RLS Global AB has reached a settlement with Dr. Karin Bergqvist
• During June 5th - 7th, the EWMA Conference (European Wound Management Association) took place in Gothenburg
• ChloraSolv registration for Australia initiated


During the third quarter
• ChloraSolv registration is now filed for Australia
• A product specialist joined and will drive the ChloraSolv commercialization for the Swedish Market
• An extra General Meeting was held on August 19th
• A directed share issue in September generated approx. MSEK 50 in new funding

Trading place and certified advisor
RLS Global’s shares has been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 8 463 83 00, Email: certifiedadviser@penser.se. During the period 2012 - 2017, the company was listed on Aktietorget.

Contact information
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Phone: +46 702 48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Phone: +46 730 23 13 57

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS  Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv®, Perisolv® and Carisolv®. The company is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser, telephone +46 (0) 8 463 83 00, email: certified adviser@penser.se. Read more at www.rls.global


Documents & Links